Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Guardant Health, Inc. - Common Stock (NQ:GH)

95.77 +0.07 (+0.07%)
Streaming Delayed Price Updated: 3:24 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Guardant Health (GH) Q1 2026 Earnings Transcript ↗
Guardant Health (GH) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
GH Q1 Deep Dive: Shield Volume Acceleration and Oncology Portfolio Expansion Fuel Growth
Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q1 CY2026, with sales up 48.3% year on year to $301.7 million. The ... 
Via StockStory
News headline image
Guardant Health (NASDAQ:GH) Delivers Impressive Q1 CY2026, Stock Soars
Diagnostics company Guardant Health (NASDAQ:GH) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 48.3% year on year to $... 
Via StockStory
Guardant Health (NASDAQ:GH) Smashes Q1 Estimates, Raises Full-Year Guidance on Soaring Screening Revenue ↗
Via Chartmill
News headline image
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Earnings: What To Look For From GH
Diagnostics company Guardant Health (NASDAQ:GH) will be reporting results this Thursday after the bell. Here’s what you need to know. Guardant Health beat an... 
Via StockStory
News headline image
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agenci... 
Via StockStory
Topics Government Stocks
News headline image
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou... 
Via StockStory
News headline image
Why Is Guardant Health (GH) Stock Soaring Today
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 5.9% in the afternoon session after the company announced that real-world evi... 
Via StockStory
Topics Government Stocks
News headline image
Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Guardant Health (GH) Stock Is Falling Today
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) fell 3% in the afternoon session after major indices including the S&P 500 and Dow J... 
Via StockStory
Topics Artificial Intelligence Economy Government
News headline image
3 Growth Stocks We Think Twice About
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
News headline image
Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics
CHICAGO — In a move that fundamentally reshapes the global diagnostics landscape, Abbott Laboratories (NYSE: ABT) officially completed its $21 billion acquisition of Exact Sciences (NASDAQ: EXAS)... 
Via MarketMinute
Topics Supply Chain
News headline image
3 Reasons to Avoid GH and 1 Stock to Buy Instead
What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 46.9%, hitting $86.90. This was partly thanks to its solid ... 
Via StockStory
Topics Supply Chain
News headline image
Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership
From Guardant Health, Inc.
Via Business Wire
News headline image
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗
This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗
This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗
Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics
From Guardant Health, Inc.
Via Business Wire
News headline image
1 Russell 2000 Stock on Our Watchlist and 2 We Question
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou... 
Via StockStory
Topics Supply Chain
News headline image
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America
From Guardant Health, Inc.
Via Business Wire
News headline image
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened
From Guardant Health, Inc.
Via Business Wire
News headline image
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. 
Via StockStory
Topics Economy Stocks
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.